Australia is closely watching the arrival of retatrutide, a innovative dual GIP and GLP-1 receptor agonist , representing a exciting advance in obesity treatment . Early clinical trials have demonstrated https://bike-giant-stance937981.illawiki.com/2801581/new_treatment_in_australia_a_new_breakthrough_for_weight_loss